Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1999 Sep;43(9):2317–2319. doi: 10.1128/aac.43.9.2317

Relationship between Pyrazinamide Resistance, Loss of Pyrazinamidase Activity, and Mutations in the pncA Locus in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis

M Mestdagh 1, P A Fonteyne 2, L Realini 2, R Rossau 3, G Jannes 3, W Mijs 3, K A L De Smet 3, F Portaels 2, E Van den Eeckhout 1,*
PMCID: PMC89471  PMID: 10471589

Abstract

Sixty-two Mycobacterium tuberculosis isolates were tested for pyrazinamidase activity, and their pyrazinamide susceptibility was determined by the radiometric method. Sequencing of pncA genes in the 23 resistant strains revealed mutations in 16 pyrazinamidase-negative strains, 11 of which had not been previously described. Six isolates containing wild-type pncA might possess alternative resistance mechanisms.


Pyrazinamide (PZA), one of the first-line drugs for tuberculosis treatment, is assumed to be a prodrug, converted by the bacterial enzyme pyrazinamidase (PZase) to the toxic pyrazinoic acid (POA), the target of which remains unknown (7). Since most PZA-resistant Mycobacterium tuberculosis strains have lost PZase activity, enzyme activity assays are sometimes used to replace PZA susceptibility testing, which is problematic because of growth problems at the acid pH (±5.5) required for in vitro activity of PZA (2, 4). Single mutations in the pncA gene encoding this PZase are considered the major PZA resistance mechanism in M. tuberculosis (5, 11, 12, 15). Our objective was to gain further insight into PZA resistance mechanisms and their molecular-biological background by comparing different methods for detection of PZA resistance in M. tuberculosis.

Fifty-four multidrug-resistant M. tuberculosis strains were isolated from clinical specimens collected in Bangladesh, Azerbaijan, Siberia, Belgium, Abkhazia, Rwanda, Congo-Brazzaville, Kazakhstan, and Canada, and eight isolates were obtained from the Scottish Mycobacteria Reference Laboratory (SMRL). M. tuberculosis H37Ra (NCTC 7417) was included as a PZA-susceptible control strain. One Mycobacterium bovis isolate from Belgium and one from Egypt from the collection of the Institute of Tropical Medicine were used as PZA-resistant control organisms. M. tuberculosis strains were grown to confluence on Löwenstein-Jensen medium, and M. bovis strains were grown on Stonebrink medium.

Isolates were tested for PZA susceptibility by the BACTEC radiometric method (3, 10, 13) at 100 μg of PZA per ml according to the manufacturer’s instructions (14).

The PZase activity of all 65 isolates was assayed, following the modified version of the Wayne (17) test, as described by Jakschik (6). For each isolate, one test tube and one control tube were prepared. The test medium contained 6.5 g of Dubos broth base (Difco Laboratories, Detroit, Mich.), 1.0 g of PZA (Janssen Chimica, Geel, Belgium), 2.0 g of sodium pyruvate (Janssen Chimica), and 15.0 g of agar (Difco Laboratories) in 1 liter of water. In the control medium, PZA was omitted. Freshly prepared autoclaved media were divided into 5-ml aliquots in glass tubes and were allowed to cool in the upright position. Next, 0.2 to 0.3 ml of sterilized water was aseptically added to both test and control tubes. Tubes were inoculated with a loopful of a freshly grown culture of each isolate by stabbing the agar two to three times onto the bottom. After incubation at 37°C for 4 days, 1.0 ml of a freshly prepared 1% ferro(II) ammonia sulfate (Acros Chimica, Geel, Belgium) solution was added to each tube, and the tubes were kept at 4°C for 4 h. A PZase activity assay was considered positive when a dark red to brownish ring appeared on the agar-water interface.

Genomic DNA was extracted as described previously (16). pncA genes were amplified by PCR (9) with primers P1 and P6 (12) to obtain DNA fragments of about 720 bp. The cycling parameters were 94°C for 1 min, 56°C for 1 min, and 72°C for 1 min; 40 cycles were performed. These PCR products were used to perform cycle sequencing by using fluorescence-labelled dideoxynucleotide terminators with the PRISM Ready Reaction Dye Deoxy Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, Calif.) and primers P1, P3, P4, and P6 (12) according to the manufacturer’s instructions. Sequence data were generated with an automated DNA sequencer, model 373A (Applied Biosystems).

Thirty-nine isolates were susceptible to PZA; they all displayed PZase activity. The pncA sequence of these isolates was not determined, because earlier investigations (11, 12, 15) of sequences in 75 PZA-susceptible M. tuberculosis strains did not reveal any nucleotide change. Twenty-three isolates were resistant to PZA. For these strains, sequencing of the pncA open reading frame and an 85-bp upstream, putative regulatory region was performed. The results obtained are summarized in Table 1. In 16 PZA-resistant isolates, the lack of PZase activity was correlated with mutations leading to amino acid substitutions (10 of 16), large deletions (1 of 16), frameshifts (4 of 16) by single nucleotide insertion or deletion, or promoter mutations (1 of 16). In four PZA-resistant isolates lacking PZase activity, wild-type pncA sequence was present. Three PZA-resistant isolates displayed PZase activity: the wild-type pncA sequence was present in two of them, while the other contained a nucleotide change leading to an amino acid substitution (isolate 98-32 [Ala to Val at codon 171]). For strains with discrepant results between susceptibility testing and the PZase assay (PZA resistant, but PZase positive) or between the PZase assay and pncA sequencing (PZase negative, but pncA wild type), the results obtained were confirmed in a second test round.

TABLE 1.

PZase activity, changes in pncA nucleotide sequence, and corresponding amino acid changes of the 23 PZA-resistant M. tuberculosis isolates in this study

Isolate Origin PZase assay result Change(s) in:
Nucleotide sequence Amino acid sequence
8251 Rwanda Δ C at 512 Frameshift
94-735 Congo + No No
97-56 Siberia No No
97-58 Siberia No No
97-69 Siberia No No
97-553 Belgium C to G at 514 and T to C at 515 L172A
97-557 Belgium C to G at 514 and T to C at 515 L172A
97-578 Bangladesh C to T at 425a T142M
97-718 Azerbaijan T to G at 254 L85R
97-720 Azerbaijan C insertion 407–408 Frameshift
97-826 Canada T to C at 307 Y103H
97-854 Bangladesh G to A at 511 A171T
97-983 Bangladesh No No
97-1006 Bangladesh A to C at 410a H137P
97-1052 Azerbaijan + No No
97-1069 Azerbaijan Δ 68 bp 195–263 Frameshift
97-1174 Azerbaijan C to A at 185 P62H
98-29 Scotland G insertion 221–222 Frameshift
98-30 Scotland G insertion 221–222 Frameshift
98-31 Scotland C to T at 151 H51Y
98-32 Scotland + C to T at 512 A171V
98-34 Scotland G to C at 406 D136H
98-36 Scotland A to G at −11b No
a

Previously described mutations (12). 

b

Previously described mutation (15). 

Detection of PZase activity, as described by Wayne (17) and modified by Jakschik (6), is an easy and very rapid technique suited for any mycobacterial laboratory. Considering BACTEC PZA susceptibility determination as a reference, PZase negativity was correlated with PZA resistance in all 20 strains in this study. However, for only 39 of the 42 PZase-positive strains, a PZA-susceptible pattern was obtained on BACTEC. This confirms the findings of Butler and Kilburn (1) and Miller et al. (8) that PZA-resistant isolates are not always PZase negative. Our conclusion is that PZase test results should only be interpreted in one direction—a negative result indicating PZA resistance—whereas care should be taken in interpreting positive test results.

Mutations were present in 17 (74%) of the 23 PZA-resistant isolates as defined by the BACTEC radiometric method. The six strains lacking pncA mutations are divided into two groups by the PZase test: one group of two strains was PZase positive, and a second group of four strains was PZase negative. Resistance to PZA in the first group may be due to mutations in the POA drug target, which has not yet been found. The second group could have undergone downregulation of the pncA gene, directed on the translation phase or on regulation of transcription, as an alternative to inactivation of the gene product by point mutations in the open reading frame. Two of these strains had a completely identical restriction fragment length polymorphism pattern (97-56 and 97-58 [data not shown]). Additional research on these strains should help to elucidate the mechanism of action of the antituberculous agent POA.

Acknowledgments

This work was supported by a grant of the Institute for Enhancement of the Scientific-Technological Research in the Industry (IWT) of the Flemish Government and by grant no. G.0368.98 of the Funding for Scientific Research in Belgium.

Clinical specimens from Bangladesh were obtained thanks to A. Van Deun, and eight M. tuberculosis isolates were obtained from the Scottish Mycobacteria Reference Laboratory thanks to John Norton (Murex Biotech Limited). We thank the team of M. Van Montagu (University of Ghent) for preparation of the primers.

REFERENCES

  • 1.Butler W R, Kilburn J O. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob Agents Chemother. 1983;24:600–601. doi: 10.1128/aac.24.4.600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cutler R R, Wilson P, Villarroel J, Clarke F V. Evaluating current methods for determination of the susceptibility of mycobacteria to pyrazinamide, conventional, radiometric Bactec and two methods of pyrazinamidase testing. Lett Appl Microbiol. 1997;24:127–132. doi: 10.1046/j.1472-765x.1997.00367.x. [DOI] [PubMed] [Google Scholar]
  • 3.Heifets L B, Good R C. Current laboratory methods for the diagnosis of tuberculosis. In: Bloom B R, editor. Tuberculosis: pathogenesis, protection and control. Washington, D.C: American Society for Microbiology; 1994. pp. 85–110. [Google Scholar]
  • 4.Hewlett D, Jr, Horn D L, Alfalla C. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA. 1995;273:916–917. [PubMed] [Google Scholar]
  • 5.Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber Lung Dis. 1998;78:117–122. doi: 10.1016/s0962-8479(98)80004-x. [DOI] [PubMed] [Google Scholar]
  • 6.Jakschik M. Reports of the Paris 30 Sept. – 1 Oct. 1985 Sessions of the IUAT Scientific Committees. Bull Int Union Tuberc. 1986;61:57–61. [Google Scholar]
  • 7.Konno K, Feldmann F M, McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis. 1967;95:461–469. doi: 10.1164/arrd.1967.95.3.461. [DOI] [PubMed] [Google Scholar]
  • 8.Miller M A, Thibert L, Desjardins F, Siddiqi S H, Dascal A. Testing of susceptibility to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J Clin Microbiol. 1995;33:2468–2470. doi: 10.1128/jcm.33.9.2468-2470.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Saiki R K, Gelfand D H, Stoffel S, Scharf S J, Higuchi R, Horn G T, Mullis K B, Erlich H A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239:487–491. doi: 10.1126/science.2448875. [DOI] [PubMed] [Google Scholar]
  • 10.Salfinger M, Heifets L B. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother. 1988;32:1002–1004. doi: 10.1128/aac.32.7.1002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med. 1996;2:662–667. doi: 10.1038/nm0696-662. [DOI] [PubMed] [Google Scholar]
  • 12.Scorpio A, Lindholm-Lévy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y. Characterization of the pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1997;41:540–543. doi: 10.1128/aac.41.3.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Siddiqi S H. Radiometric (BACTEC) tests for slowly growing mycobacteria. In: Isenberg H D, editor. Clinical microbiology procedures handbook. Vol. 1. Washington, D.C: American Society for Microbiology; 1992. pp. 5.14.1–5.14.25. [Google Scholar]
  • 14.Siddiqi S H. BACTEC TB system, product and procedure manual. Towson, Md: Becton Dickinson Diagnostic Instruments Systems; 1989. [Google Scholar]
  • 15.Sreevatsan S, Pan X, Zhang Y, Kreiswirth B N, Musser J M. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother. 1997;41:636–640. doi: 10.1128/aac.41.3.636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.van Soolingen D, Hermans P W M, de Haas P E W, Soll D R, van Embden J D A. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol. 1991;29:2578–2586. doi: 10.1128/jcm.29.11.2578-2586.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wayne L G. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis. 1974;109:147–151. doi: 10.1164/arrd.1974.109.1.147. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES